Monday, December 29, 2014
Home
Methergine

Methergine


View Stages of Pregnancy Slideshow Pictures

Methergine Drug Description


Methergine®
(methylergonovine maleate) Tablets, USP
(methylergonovine maleate) Injection, USP

DRUG DESCRIPTION

Methergine® (methylergonovine maleate) is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage.

Methergine (methylergonovine maleate) is available in sterile ampuls of 1 mL, containing 0.2 mg methylergonovine maleate for intramuscular or intravenous injection and in tablets for oral ingestion containing 0.2 mg methylergonovine maleate.

Tablets

Active Ingredient: methylergonovine maleate, USP, 0.2 mg.

Inactive Ingredients: acacia, carnauba wax, D&C Red #7, FD&C Blue #1, gelatin special, lactose, maleic acid, mixed parabens, povidone, sodium benzoate, sodium hydroxide, starch, stearic acid, sucrose, talc, and titanium dioxide.

Ampuls, 1 mL, clear, colorless solution.

Active Ingredient: methylergonovine maleate, USP, 0.2 mg.

Inactive Ingredients: maleic acid, 0.10 mg; sodium chloride, 7.0 mg; water for injection, qs to 1 mL.

Chemically, methylergonovine maleate is designated as ergoline-8-carboxamide, 9,10-didehydro-N-[1-(hydroxymethyl)propyl]-6-methyl-, [8β(S)]-, (Z)-2-butenedioate (1:1) (salt).

Its structural formula is

Methergine (methylergonovine maleate) structural formula illustration

 

What are the possible side effects of methylergonovine (Methergine)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

  • increased blood pressure (severe headache, blurred vision);
  • seizure (convulsions);
  • feeling light-headed, fainting;
  • pounding heartbeat;
  • chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;...

Read All Potential Side Effects and See Pictures of Methergine »

 

What are the precautions when taking methylergonovine maleate (Methergine)?

Before taking methylergonovine, tell your doctor or pharmacist if you are allergic to it; or to similar ergot alkaloids (such as ergonovine); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, liver disease, high blood pressure, heart disease (such as venoatrial shunts, mitral valve stenosis), blood vessel disease (such as Raynaud's disease), complications during pregnancy (such as preeclampsia, eclampsia).

This drug may make you dizzy. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can...

 

Methergine

Methergine Indications & Dosage


INDICATIONS

For routine management after delivery of the placenta; postpartum atony and hemorrhage; subinvolution. Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder.

DOSAGE AND ADMINISTRATION

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

Intramuscularly

1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours.

Intravenously

Dosage same as intramuscular. (See WARNINGS.)

Orally

One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.

HOW SUPPLIED

Tablets

0.2 mg round, coated, orchid, branded “78-54” one side, “SANDOZ” other side.

Bottles of 100............................NDC 0078-0054-05

Ampuls

1 mL size

Boxes of 20...............................NDC 0078-0053-03

Store and Dispense

Tablets: Store below 25°C (77°F); in tight, light-resistant container.

Ampuls: Store in refrigerator, 2°C-8°C (36°F-46°F). Protect from light. Administer only if solution is clear and colorless.

Distributed by: Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936. FDA Rev date: 4/26/2007

 

 

Methergine


Methergine Side Effects & Drug Interactions


SIDE EFFECTS

The most common adverse reaction is hypertension associated in several cases with seizure and/or headache. Hypotension has also been reported. Nausea and vomiting have occurred occasionally. Rarely observed reactions have included: acute myocardial infarction, transient chest pains, arterial spasm (coronary and peripheral), bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste.1

There have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product.

Drug Abuse And Dependence

Methergine® (methylergonovine maleate) has not been associated with drug abuse or dependence of either a physical or psychological nature.

DRUG INTERACTIONS

CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors)

There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. Although there have been no reports of such interactions with methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine. Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Less potent CYP 3A4 inhibitors should be administered with caution. Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine.

No pharmacokinetic interactions involving other cytochrome P450 isoenzymes are known.

Caution should be exercised when Methergine® (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.

1. Information on Adverse Reactions supplied by Medical Services Department, Novartis Pharmaceuticals, E. Hanover, N.J., based on computerized clinical reports.

 

Methergine


 

Methergine Warnings & Precautions


WARNINGS

This drug should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V. administration is considered essential as a lifesaving measure, Methergine® (methylergonovine maleate) should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Intra-arterial or periarterial injection should be strictly avoided.

PRECAUTIONS

General

Caution should be exercised in the presence of sepsis, obliterative vascular disease, hepatic or renal involvement. Also use with caution during the second stage of labor. The necessity for manual removal of a retained placenta should occur only rarely with proper technique and adequate allowance of time for its spontaneous separation.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term studies have been performed in animals to evaluate carcinogenic potential. The effect of the drug on mutagenesis or fertility has not been determined.

Pregnancy

Category C. Animal reproductive studies have not been conducted with Methergine. It is also not known whether methylergonovine maleate can cause fetal harm or can affect reproductive capacity. Use of Methergine (methylergonovine maleate) is contraindicated during pregnancy because of its uterotonic effects. (See INDICATIONS AND USAGE.)

Labor and Delivery

The uterotonic effect of Methergine (methylergonovine maleate) is utilized after delivery to assist involution and decrease hemorrhage, shortening the third stage of labor.

Nursing Mothers

Methergine® (methylergonovine maleate) may be administered orally for a maximum of 1 week postpartum to control uterine bleeding. Recommended dosage is 1 tablet (0.2 mg) 3 or 4 times daily. At this dosage level a small quantity of drug appears in mothers' milk. Caution should be exercised when Methergine (methylergonovine maleate) is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

Clinical studies of Methergine (methylergonovine maleate) did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

 

Methergine


Methergine Overdosage & Contraindications


OVERDOSE

Symptoms of acute overdose may include: nausea, vomiting, abdominal pain, numbness, tingling of the extremities, rise in blood pressure, in severe cases followed by hypotension, respiratory depression, hypothermia, convulsions, and coma.

Because reports of overdosage with Methergine® (methylergonovine maleate) are infrequent, the lethal dose in humans has not been established. The oral LD50 (in mg/kg) for the mouse is 187, the rat 93, and the rabbit 4.5.2 Several cases of accidental Methergine (methylergonovine maleate) injection in newborn infants have been reported, and in such cases 0.2 mg represents an overdose of great magnitude. However, recovery occurred in all but one case following a period of respiratory depression, hypothermia, hypertonicity with jerking movements, and, in one case, a single convulsion.

Also, several children 1-3 years of age have accidentally ingested up to 10 tablets (2 mg) with no apparent ill effects. A postpartum patient took 4 tablets at one time in error and reported paresthesias and clamminess as her only symptoms.

Treatment of acute overdosage is symptomatic and includes the usual procedures of:

  1. removal of offending drug by inducing emesis, gastric lavage, catharsis, and supportive diuresis.
  2. maintenance of adequate pulmonary ventilation, especially if convulsions or coma develop.
  3. correction of hypotension with pressor drugs as needed.
  4. control of convulsions with standard anticonvulsant agents.
  5. control of peripheral vasospasm with warmth to the extremities if needed.3

CONTRAINDICATIONS

Hypertension; toxemia; pregnancy; and hypersensitivity.

2. Berde, B. and Schild, H.O.: Ergot Alkaloids and Related Compounds, Springer-Verlag, New York, 1978, p. 810.
3.   Treatment of Acute Overdosage. Novartis Consumer Health, Inc. Rx Products. Novartis, Medical Services Department.

 

Methergine

Methergine Clinical Pharmacology


CLINICAL PHARMACOLOGY

Methergine® (methylergonovine maleate) acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I.V. administration is immediate; after I.M. administration, 2-5 minutes, and after oral administration, 5-10 minutes.

Pharmacokinetic studies following an I.V. injection have shown that methylergonovine is rapidly distributed from plasma to peripheral tissues within 2-3 minutes or less. The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses. During delivery, with intramuscular injection, bioavailability increased to 78%. Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver.

Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours. For a 0.2 mg intramuscular injection, a mean peak plasma concentration of 5918 ± 1952 pg/mL was observed at 0.41 ± 0.21 hours. The extent of absorption of the tablet, based upon methylergonovine plasma concentrations, was found to be equivalent to that of the I.M. solution given orally, and the extent of oral absorption of the I.M. solution was proportional to the dose following administration of 0.1, 0.2, and 0.4 mg. When given intramuscularly, the extent of absorption of Methergine (methylergonovine maleate) solution was about 25% greater than the tablet. The volume of distribution (Vdss/F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour. The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours). A delayed gastrointestinal absorption (Tmax about 3 hours) of Methergine (methylergonovine maleate) tablet might be observed in postpartum women during continuous treatment with this oxytocic agent.

 

Methergine


Methergine Medication Guide


PATIENT INFORMATION

No information provided. Please refer to the WARNINGS and PRECAUTIONS sections.

 

Methergine

Methergine Consumer

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

 

METHYLERGONOVINE - ORAL

 

(METH-ill-er-go-NO-veen)

 

COMMON BRAND NAME(S): Methergine

 

USES: This medication is used after childbirth to help stop bleeding from the uterus. Methylergonovine belongs to a class of drugs known as ergot alkaloids. It works by increasing the rate and strength of contractions and the stiffness of the uterus muscles. These effects help to decrease bleeding.

 

HOW TO USE: Take this medication by mouth with or without food, usually 3 to 4 times daily for up to 1 week after delivery or as directed by your doctor.

Dosage is based on your medical condition and response to treatment.

Use this medication regularly to get the most benefit from it. To help you remember, take it at the same times each day.

Avoid eating grapefruit or drinking grapefruit juice while using this medication unless your doctor instructs you otherwise. Grapefruit can increase the amount of this medication in your bloodstream. Consult your doctor or pharmacist for more details.

Tell your doctor if your condition persists or worsens.

 

Methergine

Methergine Consumer (continued)

SIDE EFFECTS: Headache, nausea, vomiting, or dizziness may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor immediately if any of these rare but serious side effects occur: fast/slow heartbeat, shortness of breath, cold hands/feet, pain/redness/swelling of arms or legs.

Seek immediate medical attention if any of these rare but serious side effects occur: chest pain, vision changes, confusion, seizures.

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

 

PRECAUTIONS: Before taking methylergonovine, tell your doctor or pharmacist if you are allergic to it; or to similar ergot alkaloids (such as ergonovine); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, liver disease, high blood pressure, heart disease (such as venoatrial shunts, mitral valve stenosis), blood vessel disease (such as Raynaud's disease), complications during pregnancy (such as preeclampsia, eclampsia).

This drug may make you dizzy. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely. Limit alcoholic beverages.

This medication must not be used during pregnancy. It may harm an unborn baby. Consult your doctor for more details.

This medication passes into breast milk, but is unlikely to harm a nursing infant. Consult your doctor before breast-feeding.

 

 

Methergine

Methergine Consumer (continued)

DRUG INTERACTIONS: See also How to Use section.

The effects of some drugs can change if you take other drugs or herbal products at the same time. This can increase your risk for serious side effects or may cause your medications not to work correctly. These drug interactions are possible, but do not always occur. Your doctor or pharmacist can often prevent or manage interactions by changing how you use your medications or by close monitoring.

To help your doctor and pharmacist give you the best care, be sure to tell your doctor and pharmacist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products) before starting treatment with this product. While using this product, do not start, stop, or change the dosage of any other medicines you are using without your doctor's approval.

Some products that may interact with this drug include: other ergot alkaloids (such as ergotamine, dihydroergotamine), "triptan" migraine medications (such as eletriptan, rizatriptan, sumatriptan).

Other medications can affect the removal of methylergonovine from your body, which may affect how methylergonovine works. Examples include azole antifungals (such as itraconazole, ketoconazole), macrolide antibiotics (such as erythromycin, clarithromycin), HIV protease inhibitors (such as ritonavir), HIV NNRTI's (such as delavirdine, efavirenz), among others.

This document does not contain all possible drug interactions. Keep a list of all the products you use. Share this list with your doctor and pharmacist to lessen your risk for serious medication problems.

 

OVERDOSE: If overdose is suspected, contact a local poison control center or emergency room immediately. US residents can call the US National Poison Hotline at 1-800-222-1222. Canada residents should call a provincial poison control center. Symptoms of overdose may include: severe headache, severe dizziness, seizures, slow/shallow breathing, numbness/tingling of arms/legs.

 

NOTES: Do not share this medication with others.

Laboratory and/or medical tests (such as blood pressure measurements) may be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

 

MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

 

STORAGE: Store at room temperature below 77 degrees F (25 degrees C) away from light and moisture. Do not store in the bathroom. Keep all medicines away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

 

Methergine


Methergine Patient Information Including Side Effects

Brand Names: Methergine

Generic Name: methylergonovine (Pronunciation: meth il er GON o veen)

 

  • What is methylergonovine (Methergine)?
  • What are the possible side effects of methylergonovine (Methergine)?
  • What is the most important information I should know about methylergonovine (Methergine)?
  • What should I discuss with my health care provider before taking methylergonovine (Methergine)?
  • How should I take methylergonovine (Methergine)?
  • What happens if I miss a dose (Methergine)?
  • What happens if I overdose (Methergine)?
  • What should I avoid while receiving methylergonovine (Methergine)?
  • What other drugs will affect methylergonovine (Methergine)?
  • Where can I get more information?

 

What is methylergonovine (Methergine)?

Methylergonovine is in a group of drugs called ergot alkaloids. It affects the smooth muscle of a woman's uterus, improving the muscle tone as well as the strength and timing of uterine contractions.

Methylergonovine is used just after a baby is born, to help deliver the placenta (also called the "afterbirth"). It is also used to help control bleeding and other uterine problems after childbirth.

Methylergonovine may also be used for purposes other than those listed in this medication guide.

Methergine 0.2 mg

round, pink, imprinted with SANDOZ, 78-54

What are the possible side effects of methylergonovine (Methergine)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

  • increased blood pressure (severe headache, blurred vision);
  • seizure (convulsions);
  • feeling light-headed, fainting;
  • pounding heartbeat;
  • chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling; or
  • hallucinations.

Other less serious side effects are more likely to occur, such as:

  • nausea, vomiting, diarrhea;
  • leg cramps;
  • dizziness;
  • ringing in your ears;
  • stuffy nose; or
  • unpleasant taste in your mouth.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.

What is the most important information I should know about methylergonovine (Methergine)?

This medication is to be used only after delivery of your baby.

Methylergonovine may pass into breast milk in small amounts and could affect a nursing baby. In some cases, you will need to use this medication for up to 1 week after your baby is born. Talk with your doctor about whether you should breast-feed during that time. You may need to use a breast pump to establish and maintain your milk flow until your methylergonovine treatment is finished.

Seek emergency medical attention if you think you have used too much of this medicine. Symptoms of a methylergonovine overdose may include nausea, vomiting, stomach pain, numbness or tingling, muscle twitching, feeling light-headed, fainting, shallow breathing, coldness, or seizure (convulsions).

There may be other drugs that can affect methylergonovine. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Grapefruit and grapefruit juice may interact with methylergonovine. The interaction could lead to potentially dangerous effects. Discuss the use of grapefruit products with your doctor. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor.

Related Drug Centers
  • Methergine

 

 

Methergine

Methergine Patient Information including How Should I Take

In this Article

  • What is methylergonovine (Methergine)?
  • What are the possible side effects of methylergonovine (Methergine)?
  • What is the most important information I should know about methylergonovine (Methergine)?
  • What should I discuss with my health care provider before taking methylergonovine (Methergine)?
  • How should I take methylergonovine (Methergine)?
  • What happens if I miss a dose (Methergine)?
  • What happens if I overdose (Methergine)?
  • What should I avoid while receiving methylergonovine (Methergine)?
  • What other drugs will affect methylergonovine (Methergine)?
  • Where can I get more information?

What should I discuss with my health care provider before taking methylergonovine (Methergine)?

You should not take this medication if you have:

  • high blood pressure;
  • toxemia of pregnancy; or
  • if your baby has not yet been born.

If you have any of these conditions, you may not be able to take methylergonovine, or you may need a dosage adjustment or special tests during treatment.

FDA pregnancy category C. This medication may be harmful to an unborn baby. It is to be used only after delivery of your baby. Tell your doctor if you become pregnant during treatment.

Methylergonovine may pass into breast milk in small amounts and could affect a nursing baby. In some cases, you will need to use this medication for up to 1 week after your baby is born. Talk with your doctor about whether you should breast-feed during that time. You may need to use a breast pump to establish and maintain your milk flow until your methylergonovine treatment is finished.

How should I take methylergonovine (Methergine)?

Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor.

Take this medicine with a full glass of water.

Methylergonovine should not be used for longer than 1 week unless your doctor has told you otherwise.

Store methylergonovine at room temperature away from light, moisture, and heat.

Related Drug Centers
  • Methergine

 

Methergine


Methergine Patient Information including If I Miss a Dose

In this Article

  • What is methylergonovine (Methergine)?
  • What are the possible side effects of methylergonovine (Methergine)?
  • What is the most important information I should know about methylergonovine (Methergine)?
  • What should I discuss with my health care provider before taking methylergonovine (Methergine)?
  • How should I take methylergonovine (Methergine)?
  • What happens if I miss a dose (Methergine)?
  • What happens if I overdose (Methergine)?
  • What should I avoid while receiving methylergonovine (Methergine)?
  • What other drugs will affect methylergonovine (Methergine)?
  • Where can I get more information?

What happens if I miss a dose (Methergine)?

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at the next regularly scheduled time. Do not take extra medicine to make up the missed dose.

What happens if I overdose (Methergine)?

Seek emergency medical attention if you think you have used too much of this medicine. Symptoms of a methylergonovine overdose may include nausea, vomiting, stomach pain, numbness or tingling, muscle twitching, feeling light-headed, fainting, shallow breathing, coldness, or seizure (convulsions).

What should I avoid while receiving methylergonovine (Methergine)?

Grapefruit and grapefruit juice may interact with methylergonovine. The interaction could lead to potentially dangerous effects. Discuss the use of grapefruit products with your doctor. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor.

What other drugs will affect methylergonovine (Methergine)?

Before taking methylergonovine, tell your doctor if you are using any of the following drugs:

  • zileuton (Zyflo);
  • antibiotics such as erythromycin (Ery-Tab, Erythrocin, E.E.S), clarithromycin (Biaxin), troleandomycin (Tao);
  • fluoxetine (Prozac), fluvoxamine (Luvox);
  • clotrimazole (Mycelex Troche), fluconazole (Diflucan), ketoconazole (Nizoral), itraconazole (Sporanox), voriconazole (Vfend);
  • other ergot medicines such as methysergide (Sansert), ergotamine (Ergostat, Medihaler, Cafergot, Ercaf, Wigraine), or dihydroergotamine mesylate (D.H.E., Migranal Nasal Spray); or
  • HIV medicines such as delaviridine (Rescriptor), indinavir (Crixivan), ritonavir (Norvir), saquinavir (Invirase), or nelfinavir (Viracept).

If you are using any of these drugs, you may not be able to use methylergonovine, or you may need dosage adjustments or special tests during treatment.

There may be other drugs not listed that can affect methylergonovine. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Where can I get more information?

Your pharmacist has more information about methylergonovine written for health professionals that you may read.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.


 

Related Drug Centers
  • Methergine
Share
 
Ruai Pharm Stats